Centers for Disease Control and Prevention
Respiratory Diseases Branch
Ryan Gierke is an epidemiologist with the Respiratory Diseases Branch at the Centers for Disease Control and Prevention (CDC). He earned his BS in Microbiology and MPH in Epidemiology from the University of Minnesota. He has over 12 years of experience in infectious disease surveillance, working at the Minnesota Department of Health (MDH) Foodborne Diseases Unit, the Georgia Emerging Infections Program, and the CDC's Active Bacterial Core Surveillance system.
Moderator of 1 Session
Session Type
Meet-the-Expert Session
Date
Tue, 21.06.2022
Session Time
13:30 - 14:30
Room
Grand Ballroom West
Chair(s)
Session Description
In this session we will present data from our respective countries on the main serotypes that are emerging to be dominant in the post higher valency vaccine use era (i.e. post 13vPCV/10vPCV) and discuss the interpretation of that data in terms of serotype replacement.
We will touch on definitions and views on the possible mechanisms of serotype replacement. We will also focus on changes in serotype 3 disease, what effect COVID-19 pandemic would have had on serotype profile of pneumococcal disease and the place of new higher valency PCVs becoming available now (such as 15vPCV and 20vPCV) in addressing replacement disease.
We believe that this session will help attendees in interpreting pneumococcal disease epidemiology following vaccine use and understand changes in serotype distribution in the context of replacement. There will be learnings from the data we will discuss that mainly reflect what occurred in countries with mature PCV programs for other settings that have introduced PCVs more recently and also those yet considering PCV use.
Please note: All MTE sessions are designed to encourage active learning and to concentrate on close interaction between audience and speakers. The MTE session organisers have provided at least 15 minutes for active discussions in their agenda.
We will touch on definitions and views on the possible mechanisms of serotype replacement. We will also focus on changes in serotype 3 disease, what effect COVID-19 pandemic would have had on serotype profile of pneumococcal disease and the place of new higher valency PCVs becoming available now (such as 15vPCV and 20vPCV) in addressing replacement disease.
We believe that this session will help attendees in interpreting pneumococcal disease epidemiology following vaccine use and understand changes in serotype distribution in the context of replacement. There will be learnings from the data we will discuss that mainly reflect what occurred in countries with mature PCV programs for other settings that have introduced PCVs more recently and also those yet considering PCV use.
Please note: All MTE sessions are designed to encourage active learning and to concentrate on close interaction between audience and speakers. The MTE session organisers have provided at least 15 minutes for active discussions in their agenda.